Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635596 | 0.82 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL320232 | 0.82 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL30531662 | 0.82 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL31683702 | 0.82 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL12729977 | 0.80 | PRKCA (0.35) | PRKCA | |
| SCHEMBL7960059 | 0.80 | LMNA (0.47) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4836149 | 0.80 | LMNA (0.47) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL528840 | 0.79 | KDM4E (0.43) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL23675028 | 0.78 | LMNA (0.46) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL2781384 | 0.78 | LMNA (0.46) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173106-B2 | Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener | JOHNSON & JOHNSON CONSUMER INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-10357444-B2 | Clear suspending personal care cleansing compositions | JOHNSON & JOHNSON CONSUMER INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180185263-A1 | CLEAR SUSPENDING PERSONAL CARE CLEANSING COMPOSITIONS | KENVUE BRANDS LLC | 2018-07-05 | — | — | US | disclosed |
| US-9937118-B2 | Clear suspending personal care cleansing compositions | JOHNSON & JOHNSON CONSUMER INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170360680-A1 | CLEAR SUSPENDING PERSONAL CARE CLEANSING COMPOSITIONS | KENVUE BRANDS LLC | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360680-A1 | CLEAR SUSPENDING PERSONAL CARE CLEANSING COMPOSITIONS | DSG1, CUTA, SNU13 | LMNA 2206/4885KDM4E 2885/4885DUSP3 3352/4885 |
| US-10357444-B2 | Clear suspending personal care cleansing compositions | DSG1, CUTA, SNU13 | LMNA 2206/4885KDM4E 2885/4885DUSP3 3352/4885 |
| US-20180185263-A1 | CLEAR SUSPENDING PERSONAL CARE CLEANSING COMPOSITIONS | DSG1, CUTA, SNU13 | LMNA 2206/4885KDM4E 2885/4885DUSP3 3352/4885 |
| US-11173106-B2 | Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener | ABHD16A, DSG1, CUTA | LMNA 3412/4885KDM4E 2986/4885DUSP3 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.